Effect of Pantoprazole on Asacol absorption in patients with Inflammatory Bowel Disease

The effectiveness and non effectiveness of Pantoprazole in the increase of Asacol absorption to treatment of inflammatory bowel disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017012227761N3

Enrollment

Registered

2017-02-05

Start date

2017-02-08

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory bowel disease. Ulcerative colitis

Interventions

In experimental group addition to the routine Asacol, Pantoprazole (40 g once per day) administered for two weeks.

Treatment - Drugs

In experimental group addition to the routine Asacol, Pantoprazole (40 g once per day) administered for two weeks

Eligibility

Sex/Gender

All

Age

17 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age between 17 to 70 years; Patients who are taking Asacol medicine tablets (400 g); Patients who have a history of drug excretion. Exclusion criteria: Patients with a history of underlying disease and hypertension drug users; Patients who are contraindicated for Asacol

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Asacol absorption. Timepoint: Baseline, the end of the study (two weeks after drug administration). Method of measurement: Based on Checklist.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSara Ghadimi noran

Kermanshah University of Medical Sciences

s.ghadimi@gmail.com+98 83 3427 6301

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026